Mesothelioma Clinical Trials

31 studies are recruiting for mesothelioma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Houston, Texas 11 New York, New York 9 Boston, Massachusetts 7 Bethesda, Maryland 6 Chicago, Illinois 6 Rochester, Minnesota 6 Columbus, Ohio 5 Fairfax, Virginia 5 Jacksonville, Florida 5 Nashville, Tennessee 5 Phoenix, Arizona 5 Seattle, Washington 5 Omaha, Nebraska 4 Pittsburgh, Pennsylvania 4 St Louis, Missouri 4 Dallas, Texas 3 Fort Worth, Texas 3 Irving, Texas 3 La Jolla, California 3 Los Angeles, California 3 San Antonio, Texas 3 Santa Rosa, California 3 Tampa, Florida 3

Studies, page 2

  1. Stereotactic Magnetic Resonance Guided Radiation Therapy

    This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Ph…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Brigham & Women's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT04115254 on ClinicalTrials.gov

  2. Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU

    Dynamic digital radiography (DDR) is a new advanced version of chest radiography that captures dynamic images at a rate of 15 frames per second. It is coupled with an analytical software that allows it to provide more advanced measures of lung motion, ventilation, and perfusion compared to traditio…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Brigham and Women's Hospital, Boston, Massachusetts
    Run by
    Brigham and Women's Hospital

    See if you can join NCT06538376 on ClinicalTrials.gov

  3. Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

    Objectives: The investigators will test whether combination of chemoimmunotherapy or dual agent immunotherapy alone improves efficacy for patients with MPM. Primary Objectives: The primary objective is to test whether the combination of platinum-based chemotherapy and pemetrexed with durvalumab / t…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Baylor St Lukes, Houston, Texas
    Locations
    2 in total
    Run by
    Baylor College of Medicine

    See if you can join NCT05932199 on ClinicalTrials.gov

  4. Olaparib in Patients With HRD Malignant Mesothelioma

    In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Chicago Medical Center, Chicago, Illinois
    Run by
    University of Chicago

    See if you can join NCT04515836 on ClinicalTrials.gov

  5. A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

    The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Run by
    BridGene Biosciences Inc.

    See if you can join NCT06452160 on ClinicalTrials.gov

  6. First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

    This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells. Th…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
    Run by
    A&G Pharmaceutical Inc.

    See if you can join NCT05627960 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.